Praxis Precision MedicinesPRAX
Recorded

Praxis Precision Medicines Investor Day 2026

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration6 hr 34 min

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Speaker

Hope this microphone works. Good morning, everyone, and welcome to the city that, just like Praxis, never sleeps. Before I get started, it's Tim's birthday, so I just want you guys to all say happy birthday to Tim. I think we all have very eventful years at Praxis, and I'm sure Tim's is not any different. Going to make some forward-looking statements, and I'm hoping I don't vomit on stage just because I've been getting a little bit of a GI thing, and thanks for Lauren for getting me Tums. Going to talk about more exciting things today than GI, I promise you, although GI is an interesting area. At the end of the day, what I would expect all of us to come out of this is really convinced that we have what it takes to launch these drugs to get to $20 billion or more.

Speaker

On the other side, that this is going to go and happen again and again. Steve and Megan and John are going to talk a lot about what is next and what is now, so going to be going intertwining between what's we've done, a lot of the things you know, a lot of the discussions we had, but particularly what's next for this phase of the company. Don't consider this a transition. People talk about scaling, like how excited or how afraid you are about commercial. I don't think that's the way we should look into this. Think every single phase in life, as we started with a birthday, brings new joy and new challenge, and this is just one of those, that we're going to be tackling.

Speaker

I am convinced once we're done with the six hours or so please stick with us, you're going to be as convinced as I am that we are excited, a little bit worried and scared, and I actually think you should be scared if you were not with the giants we have in front of us that we need to conquer to get to the company we believe we deserve to be. But that is totally overcome by the excitement of helping these patients. Most of you heard me saying this throughout the years a number of times. There is one reason only that we are here. A lot of people in this audience, I'm certain, are dealing with something we don't know about, with a condition we don't know about, your loved ones, people you know.

Speaker

We know people here in the audience who are suffering with early stages of essential tremor, of other conditions. We think about CNS, because of this weird function of our brain, evolution tried to protect it, right. Made it a little harder for us to just go inside and take samples of it and do other things that other fields of medicine. We rely on the incredible people that dedicated their lives to CNS research to really advance the fields. We had incredible developments in CNS throughout the years, many, many years ago. Then we had a little bit of a valley of death where nothing was actually done, and a renaissance, maybe post-renaissance at this point in time, that we are seeing where we can use all those tools.

Speaker

We will continue to do this for as long as we stand here to help these patients again and again. Keep that again and again at the end there, because you are going to hear today a lot of the motivation. Sometimes that again is going to be like fighting a reimbursement decision. Sometimes that again is going to be standing up when you get a no. But oftentimes it is going to be going to an area that we believe patients deserve for us to go there, just like in the past. I am not the biggest fan of thinking about stock charts or performance as anything but a bunch of things that happen on your day, every single day, and so on, and you get sometimes overly obsessed about it.

Speaker

I thought, number 1, because this is an investor event, and number 2, because it is fairly illustrative that you take the journey and look back on the last 18 months, 24 months, three months, six months, you pick it. We just picked a point in time here. Not because of the trajectory of the stock, although I am not going to say I just like it, but particularly because it illustrates two things. Well, many things, but I am going to pick two things and then a few other things in a second. The first one is how I started this conversation, right? We definitely like New York City. There is always a lot of stuff we are trying to achieve. Now, why? The why gets missed. It is because there are people out there or inside this room that need us to do that.

Speaker

Also have an acknowledgement that you should never start something expecting not to get to the results you planned for. That is actually lunacy. This acceptance of failure that is so often from in biotech and pharma, I think is just a very easy way for cowards to say, "I am not accepting my failures," and we are never going to do that as a company. As much as you accept your successes, you must accept when your assumptions were not there. What allow us to do is to reinforce a number of the principles that are insanely important for Praxis. We can be accused of many things, one of them being incredibly successful, and please accuse us of that.

Speaker

We cannot be accused of not remain focused, being resilient or anti-fragile, if you want to, the postmodern there, to define the science, follow the actual data and not the opinions, and be convinced of what we are doing there, but also change our minds when new data becomes available, and that is through conviction. Never hiding away from accountability. All right? You are going to continue to do this again and again. I am certain by the end of the day, you are going to be even more convinced that those are certain principles we operate in everything we do, and particularly science, data, commercial, and many other things. Are we a conventional company? God knows. I do not think we have a lot of respect for convention here, and we are very comfortable with that. All of you here know what we have been talking about.

Speaker

I say we because most of you want to talk about other things with us, right? You all have your personal obsessions, and it varies by the direction of the winds, but it tends to be mostly on the last several months about ulixacaltamide hydrochloride for essential tremor, and then a little bit about relutrigine for SCN2A, and then most recently, EMERALD for DEE, and then a variance of other things. We always try to bring back a little bit the depth of what we were trying to do. Maybe one of the reasons why it was not so clear before is, one, just how large the opportunities are on the top, and then it is just easy to not pay attention to other things, which is totally fine and totally acceptable. Maybe it is because of the perennial questions like, how? How can you advance those things, right?

Speaker

It is more capital question. Maybe because we are too financially responsible, and when you are looking to analogs, it is hard to match that we are. So birthday boy helped us being there, like really focus on that and with the rest of the executive team, of course. Maybe. We do not know why. But also know that the average of all the opinions is just not to move, so we are not going to be seeking average of opinions. We are going to be seeking biology, market needs, and what these patients really needs. You will hear today that a lot of this stuff we have been doing on the background, we chose to just advance a little bit before telling you all. It is both a products of the company we are today versus the company we were years ago.

Speaker

In technical terms, the materiality threshold changes, as you all know, and we can actually mature things a little bit more in-house. I think another one is geopolitics, and I think it is important that we mature intellectual property more than ever in the U.S. But others, because we are really trying to make sure that those decisions follow the same process, the same principles we had before. So what we are going to see today is a number of things, and would need a three-day or four-day analyst day or investor day to actually be able to cover in detail everything we are going to be talking here. But as we became more and more convinced and ultimately culminating with the essential tremor successful studies for ulixacaltamide to validate our approach for T-type calcium channel developments, that that is, as you know, is fairly different than other approach that were tried before.

Speaker

We continue to advance other things on that mechanism, and Steve is going to talk a little bit more of that. It is going to come out in several areas, right? In indications that we believe are adjacent or a little bit far, but there is a little bridge there. It is going to come out as the molecules who are entering the clinic in the next few months, when we have a franchise as large as essential tremor or others indications for T-type calcium channel modulators. I think it is important that we ask not only what do I do with this one drug, but what do I do to help these patients throughout the spectrum they have? We have hypothesis that there are certain properties that might be better modulated by an isoform-specific CaV3.1, or at least a biased 3.1.

Speaker

We've been advancing that program secretly quite a lot, that's incredibly exciting. You can going on and on here in an entire cluster of genetically defined conditions that we are starting with for our RNA-based approach. It's incredibly exciting. Of course, in general, where we are today, it's more exciting when we sit here about this time next year, right? Those pipeline charts are oftentimes misleading. They give this false precision or false direction on where we are, but to really get in on where we're going to be, I challenge anyone in the audience to match a company that combines the principles, the science, the capital, and the discipline in the way that we've been executing that could move those programs without just like blowing up OPEX, right?

Speaker

Because I'm sure that on the back of your mind, you're like, "How can this be done with what we have right now in cash?" I can tell you, this is advancing, and you barely notice. Yes, it can and will continue to be done. Another way to look into this, I know one of our ex-presidents, one of the ones that were actually presidents, said this, that if you have a vision, you should reconsider, right? Because this idea of a vision is you think things are going to follow exactly how you plan, and we know full well things never follow exactly as we plan. I'm going to dare to use that a little bit and discuss what could be the minimum that we're going to have in 2035.

Speaker

2035 is not even 10 years from now, so I cannot do my best JFK impersonation here. In less than two years instead of within the decades, we expect to be even more than we are today, fully integrated CNS company, with many areas of knowledge within CNS being addressed by the programs we have. Does it diminish the importance of the next launch? Absolutely not. Is it enabled, at least in part, by those? Absolutely, yes. Right? Those things are not mutually exclusive. If you look around, there is not a single area here or in the other disease that we're going to be discussing where you can say why. When you fundamentally think on the only entity that matters, that is the patient who needs a treatment, each one of those areas has massive unmet needs.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day